IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: David Jonathan Madge et al.
Application No.: 10/658,971
Filed: September 9, 2003
Confirmation No.: 3998
For: BORONIC ACID SALTS USEFUL IN PARENTERAL FORMULATIONS
Examiner: To be assigned
Art Unit: 1615
Attorney Reference No.: 6613-66749-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney for Applicant(s) Wayne W. Rupert

Date Mailed September 15, 2005

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

☒ Supplemental Information Disclosure Statement
☒ PTO-1449 Form and copies of Non-U.S. Reference listed therein

☒ The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.

☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By Wayne W. Rupert
Wayne W. Rupert
Registration No. 34,420

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: David Jonathan Madge et al.
Application No.: 10/658,971
Filed: September 9, 2003
Confirmation No.: 3998
For: BORONIC ACID SALTS USEFUL IN PARENTERAL FORMULATIONS
Examiner: To be assigned
Art Unit: 1615
Attorney Reference No.: 6613-66749-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant(s) Wayne L. Ryder

Date Mailed September 15, 2005

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants direct the U.S. Patent and Trademark Office's attention to the fact that an Office action containing certain rejections was mailed on June 15, 2005, in related Application Serial No. 10/659,179, filed on September 9, 2003. Attached is a copy of the Office action.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this Information Disclosure Statement is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Wayne W. Rupert
Registration No. 34,420

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

WR:jam 09/15/05 6613-66749-01 427278 JHC/P041087US1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	6613-66749-01
Application Number	10/658,971
Filing Date	September 9, 2003
First Named Inventor	David Jonathan Madge
Art Unit	1615
Examiner Name	To be assigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		5,169,841	08 Dec 1992	Kleeman et al.
		6,114,308	05 Sept 2000	Claeson et al.
		6,297,217	02 Oct 2001	Adams et al.
		6,417,174	09 July 2002	Shoichet et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		Europe	EP 0 235 692	19 Feb 1987	Behringwerke Aktiengeseilschaft
		Europe	EP 0 599 633	24 Nov 1993	Thrombosis Research Institute
		WIPO/PCT	WO 89/09612	19 Oct 1989	Corvas, Inc.
		WIPO/PCT	WO 94/21668	29 Sept 1994	The DuPont Merck Pharmaceutical Company
		WIPO/PCT	WO 98/00443	08 Jan 1998	Thrombosis Research Institute

EXAMINER SIGNATURE:	DATE CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		
	Attorney Docket Number	6613-66749-01
	Application Number	10/658,971
	Filing Date	September 9, 2003
	First Named Inventor	David Jonathan Madge
	Art Unit	1615
	Examiner Name	To be assigned

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
		Bastin et al., "Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities," *Organic Process Research & Development* 4:427-235, 2000
		Brikh et al., "Boronated thiophenols: a preparation of 4-mercaptophenylboronic acid and derivatives," *Journal of Organometallic Chemistry* 581:82-86, 1999
		Davies et al., "Peroxides of Elements other than Carbon. Part XII. The Autoxidation of Optically Active 1-Phenylethylboronic Acid," *J Chem Soc* pp. 17-22, 1967
		Elgendy et al., "Design of a novel class of bifunctional thrombin inhibitors, synthesised by the first application of peptide boronates of solid phase chemistry," *Tetrahedron Letters* 38(18):3305-3308, 1997
		Hsiao et al., "A Facile Synthesis of *tert*-Butyl 2-[Benzyloxycarbonyl)amino]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propionate: An Orthogonally Protected Boronic Acid Analog of Aspartic Acid," *Synthesis* 7:1043-1046, 1998
		Kettner et al., "Inhibition of the Serine Proteases Leukocyte Elastase, Pancreatic Elastase, Cathepsin G, and Chymotrypsin by Peptide Boronic Acids," *The Journal of Biological Chemistry* 259(24)15106-15114, 1984
		Kettner et al., "The Selective Inhibition of Thrombin of Peptides of Boroarginine," *The Journal of Biological Chemistry* 265(30):18289-18297, 1990
		Lappert, "Organic Compounds of Boron," *Chem. Review* 56:959-1064, 1956
		Martichonok et al., "Cysteine Proteases such as Papain are not Inhibited by Substrate Analogue Peptidyl Boronic Acids," *Bioorganic and Medicinal Chemistry* 5(4):679-684, 1997
		Skordalakes et al., "Crystallographic Structures of Human α-Thrombin Complexed to Peptide Boronic Acids Lacking a Positive Charge of P1. Evidence of Novel Interactions," *J. Am. Chem. Soc.* 119:9935-9936, 1997
		Snyder et al., "Organoboron Compounds, and the Study of Reaction Mechanisms. Primary Aliphatic Boronic Acids," *Am Chem Soc* 60:105-111, 1938
		Snyder et al., "Aryl Boronic Acids. II. Aryl Boronic Anhydrides and their Amine Complexes," *Am Chem Soc* 80:3611-3615, 1958
		Wityak et al., "Synthesis of Thrombin Inhibitor DuP 714," *J. Org. Chem.* 60:3717-3722, 1995

EXAMINER SIGNATURE:	DATE CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.